Jones v. Invasix Inc.

CourtDistrict Court, M.D. Tennessee
DecidedFebruary 1, 2021
Docket3:19-cv-00860
StatusUnknown

This text of Jones v. Invasix Inc. (Jones v. Invasix Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jones v. Invasix Inc., (M.D. Tenn. 2021).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

MIA JONES, ) ) Plaintiff, ) ) v. ) Case No. 3:19-cv-0860 ) Judge Aleta A. Trauger INVASIX INC. and INMODE LTD., ) ) Defendants. ) )

MEMORANDUM

Defendants Invasix Inc. (“Invasix”) and InMode Ltd. (“InMode”) have filed a Motion for Summary Judgment (Doc. No. 90), to which Mia Jones has filed a Response (Doc. No. 104), the defendants have filed a Reply (Doc. No. 111), Jones has filed a Sur-Reply (Doc. No. 115), and the defendants have filed a Sur-Sur-Reply (Doc. No. 118.) Jones has filed a Motion to Strike Summary Judgment Evidence and Objection (Doc. No. 101), to which the defendants have filed a Response (Doc. No. 110). For the reasons set out herein, the defendants’ motion will be granted in part and denied in part, and Jones’ motion will be denied. I. BACKGROUND This case involves a medical device manufactured, marketed, and/or sold by the defendants under the name “Fractora.” It is used on the skin for cosmetic purposes. A detailed account of the regulatory environment surrounding the sale and marketing of the Fractora as a medical device, combined with allegations, by Jones, of various instances of wrongdoing, can be found in the court’s Memorandum of May 19, 2020. (Doc. No. 85 at 1–7.) In short, Jones alleges that the defendants marketed the Fractora improperly, including by encouraging its operation by unqualified personnel and/or in unsafe ways, leading to the device’s inflicting permanent injuries on some patients. Jones—herself an aesthetician who was trained to perform Fractora procedures—alleges that she was injured by a Fractora procedure performed on her face by another aesthetician on

November 15, 2017, likely due, at least in part, to the aesthetician’s use of a “60-pin tip,” rather than a weaker tip. On January 23, 2019, Jones and others with similar allegations entered into a Tolling Agreement with Invasix “and any other related and affiliated corporations and businesses” covering potential claims related to Fractora. On April 17, 2019, a day before the Tolling Agreement was to expire, Jones filed her claims in the U.S. District Court for the Central District of California, which later transferred the claims here. (Doc. No. 1; Doc. No. 76-4; Doc. No. 105 ¶¶ 1–2, 9.) At issue with regard to the current motion is whether those claims were timely filed, which, as the court will discuss later in this opinion, may depend, in part, on the details of when Jones became or should have become aware that she had suffered a wrongful injury, rather than the intentional, controlled physical damage inflicted during a successful Fractora procedure.

Jones concedes that the November 15, 2017 procedure immediately left her face “extremely red and a little swollen even after using a cooling device,” which condition shortly thereafter transitioned to significant scabbing. (Doc. No. 105 ¶ 3.b, at 10 ¶¶ 26–7.1) She also concedes that her post-procedure condition was sufficiently severe that it caused her to miss three days of work. (Id. ¶ 3.c, at 10 ¶ 27.) Jones, moreover, was trained in the Fractora procedure herself and had had the Fractora procedure performed on her twice before—albeit with different

1 For reasons that will be explained in this opinion, Jones’ Response to the defendants’ Statement of Undisputed Material Facts (Doc. No. 105) includes two numbered sets of paragraphs—the first, representing assertions by the defendants, and the second representing assertions by Jones. When the court cites this document, a citation to a paragraph without a page number will refer to the first set of numbered paragraphs. If a page number is included, the citation is to the second set of paragraphs. parameters—and had had no such severe reaction. Therefore, she was at least aware that the Fractora procedure did not necessarily result in post-procedure disfigurement, temporary or otherwise. Those prior procedures, however, had not involved the 60-pin tip. (Id. ¶ 3.a, at 23 ¶ 46.) As time passed and Jones’ face continued to show damage, she saw multiple physicians regarding

the matter. She has also undergone corrective laser treatments and has spent money on medications, ointments, and other products in her attempts to address the problems that, she now believes, include scarring that may well be permanently disfiguring. (Id. ¶¶ 3.d–.f.) Jones filed her April 17, 2019 Complaint with two co-plaintiffs, Heather Wanke and Janice Newman, in the Central District of California. (Doc. No. 1.) That Complaint named only Invasix as a defendant. (Id. at 1.) On June 28, 2019, Invasix filed a Motion to Sever and Transfer Plaintiffs’ Claims. (Doc. No. 20.) Invasix noted that Jones and Wanke were Tennessee residents who had procedures performed on them in Tennessee, while Newman was a New York resident whose Fractora procedure was performed in New York. Moreover, Invasix argued, each plaintiff’s claims involved unique questions regarding each patient’s treatment, rendering joinder inappropriate.

(Doc. No. 20-1 at 9.) The plaintiffs opposed the motion, arguing that their claims were based on the same course of wrongdoing by Invasix and that the Central District of California was the most convenient forum for key non-party witnesses. (Doc. No. 28 at 3, 14.) The court granted both of Invasix’s requests, severing the plaintiffs’ cases and transferring each case to the plaintiff’s home district—that being, in Jones’ case, the Middle District of Tennessee. (Doc. No. 36.) On October 22, 2019, Jones filed an Amended Complaint adding InMode as a defendant. (Doc. No. 58 at 1.) On February 27, 2020, Invasix and InMode filed separate Motions to Dismiss, each of which alleged that Jones’ claims were barred by the relevant statutes of limitations (and InMode’s arguing, in addition, that service of process on that company, which is based in Israel, was ineffective). (Doc. Nos. 67 & 69.) While those motions were pending, Jones filed a Motion for Leave to File Amended Complaint. (Doc. No. 73.) The proposed Second Amended Complaint included several new paragraphs under the heading “Facts Concerning Statute of Limitations,” the first of which explained as follows:

The Fractora procedure involves the intentional destruction of tissue so that new collagen will form, tightening and otherwise resurfacing the skin. All Fractora patients experience an injury and [patients] heal at different rates. The condition of Plaintiff’s skin worsened over time after the procedure. Plaintiff only suspected she might have suffered an unintended injury with long term changes in her skin in early 2018. Subsequently, two physicians told Plaintiff she should not be alarmed, that she could expect her skin to continue healing for up to a year and that it would be impossible to determine whether she had any actual injury (as opposed to the intentional tissue damage and expected healing time for the Fractora) for at least a year after the procedure. A year’s time confirmed that [Jones’] procedure caused an injury to her skin beyond that which is intended and she has suffered a cognizable injury caused by Defendants—permanent scarring, changes in skin texture and color and loss of volume. Thus, based on the advice of multiple [doctors], Plaintiff did not and could not through exercise of reasonable diligence [have] known she suffered a cognizable injury as a result of the Defendant’s wrongful conduct until November 15, 2018.

(Doc. No. 87 ¶ 7.) The proposed Second Amended Complaint also excised or qualified certain details that could be construed as suggesting that she was aware of the nature of her injuries relatively early in the aftermath of her procedure. (See Doc. No. 105 ¶ 15.) On May 19, 2020, the court entered a Memorandum and Order granting Jones leave to file the Second Amended Complaint. (Doc. Nos.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Yao-Wen Chang v. Baxter Healthcare Corp.
599 F.3d 728 (Seventh Circuit, 2010)
Van Dusen v. Barrack
376 U.S. 612 (Supreme Court, 1964)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Ferens v. John Deere Co.
494 U.S. 516 (Supreme Court, 1990)
Norman Redwing v. Catholic Bishop for the Diocese of Memphis
363 S.W.3d 436 (Tennessee Supreme Court, 2012)
Sherrill v. Souder
325 S.W.3d 584 (Tennessee Supreme Court, 2010)
John Kohl & Co. PC v. Dearborn & Ewing
977 S.W.2d 528 (Tennessee Supreme Court, 1998)
Stanbury v. Bacardi
953 S.W.2d 671 (Tennessee Supreme Court, 1997)
Montgomery v. Wyeth
580 F.3d 455 (Sixth Circuit, 2009)
Uhl v. Komatsu Forklift Co., Ltd.
512 F.3d 294 (Sixth Circuit, 2008)
Shadrick v. Coker
963 S.W.2d 726 (Tennessee Supreme Court, 1998)
Dalkilic v. Titan Corp.
516 F. Supp. 2d 1177 (S.D. California, 2007)
Cossman v. DaimlerChrysler Corp.
133 Cal. Rptr. 2d 376 (California Court of Appeal, 2003)
Giest v. Sequoia Ventures, Inc.
99 Cal. Rptr. 2d 476 (California Court of Appeal, 2000)
Weinstat v. Dentsply International, Inc.
180 Cal. App. 4th 1213 (California Court of Appeal, 2010)
Hinesley v. Oakshade Town Center
37 Cal. Rptr. 3d 364 (California Court of Appeal, 2005)
Scott v. Metabolite International, Inc.
9 Cal. Rptr. 3d 242 (California Court of Appeal, 2004)
Hambrecht & Quist Venture Partners v. American Medical International, Inc.
38 Cal. App. 4th 1532 (California Court of Appeal, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
Jones v. Invasix Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/jones-v-invasix-inc-tnmd-2021.